Obinutuzumab (GA101) in Combination with CHOP (Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) or Bendamustine for the First-Line Treatment of Follicular Non-Hodgkin Lymphoma: Final Results from the Maintenance Phase of the Phase Ib GAUDI Study

被引：0

作者：

Dyer, Martin J. S. ^{[1
]}

Grigg, Andrew P. ^{[2
]}

Gonzalez Diaz, Marcos ^{[3
]}

Dreyling, Martin ^{[4
]}

Rule, Simon ^{[5
]}

Lei, Guiyuan ^{[6
]}

Wassner-Fritsch, Elisabeth ^{[7
]}

Fingerle-Rowson, Geunter ^{[7
]}

Marlton, Paula V. ^{[8
]}

机构：

[1] Univ Leicester, Leicester, Leics, England

[2] Austin Hosp, Heidelberg, Vic 3084, Australia

[3] Univ Hosp Salamanca, Salamanca, Spain

[4] Univ Hosp LMU, Munich, Germany

[5] Derriford Hosp, Plymouth PL6 8DH, Devon, England

[6] Roche Prod Ltd, Welwyn Garden City AL7 3AY, Herts, England

[7] F Hoffmann La Roche Ltd, Basel, Switzerland

[8] Princess Alexandra Hosp, Brisbane, Qld 4102, Australia

来源：

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：3